SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...
Zura Bio raises $144 million to accelerate clinical trials and expand its autoimmune drug development efforts.
After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and ...
Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.
OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet. Ngenla's profit share with Pfizer has underperformed ...
SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed an independent third-party valuation ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying ...
OSE will now pivot to focus on late-stage pipeline development of its cancer vaccine, Tedopi and its anti-inflammatory drug, lusvertikimab.
35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...
After decades of frustration and failure, the landscape of drug development for Alzheimer’s disease (AD) is starting to shift beyond anti-amyloids. Fueled by a growing pipeline of investigational ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results